Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Polyrizon Ltd. ( (PLRZ) ) has shared an announcement.
On May 13, 2026, Israel-based Polyrizon announced it has signed its first Clinical Trial Agreement with a Texas clinical research site specializing in allergy studies, securing the initial U.S. location for its NASARIX (PL-14) Allergy Blocker trial. The site will participate in a planned multicenter study comparing the investigational intranasal barrier spray to saline in patients with seasonal allergic rhinitis, marking a key step in moving NASARIX from preclinical development toward first-in-human clinical validation and supporting the company’s broader regulatory strategy.
The trial, which will follow international Good Clinical Practice standards, is intended to assess safety, tolerability and efficacy of NASARIX as a non-pharmacological protective barrier against airborne allergens. With additional study sites expected to be added in the coming months, the move signals Polyrizon’s progression toward clinical-stage operations in the allergy space and may strengthen its positioning in intranasal medical devices if results are positive.
More about Polyrizon Ltd.
Polyrizon Ltd. is a development-stage biotech company focused on medical device hydrogels delivered as intranasal sprays that form a thin barrier in the nasal cavity against viruses and allergens. Its proprietary Capture and Contain (C&C) hydrogel platform is designed as a “biological mask,” and the company is also advancing early-stage Trap and Target (T&T) technology for nasal delivery of active pharmaceutical ingredients.
Average Trading Volume: 42,934
Technical Sentiment Signal: Hold
Current Market Cap: $26.76M
See more data about PLRZ stock on TipRanks’ Stock Analysis page.